These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

73 related articles for article (PubMed ID: 8353827)

  • 1. [Dynamics of the effects of levoprotiline and maprotiline on EEG in patients with major depressive episodes (DSM-III-R)].
    David I; Filip V; Höschl C; Albrecht V; Palus M; Seifertová D; Prasková H
    Cesk Psychiatr; 1993 Jun; 89(3):123-9. PubMed ID: 8353827
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmaco-EEG profile of levoprotiline: second example to discuss the predictive value of pharmaco-electroencephalography in early human pharmacological evaluations of psychoactive drugs.
    Herrmann WM; Schärer E; Wendt G; Delini-Stula A
    Pharmacopsychiatry; 1991 Nov; 24(6):206-13. PubMed ID: 1812497
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacological profile of the new antidepressant levoprotiline.
    Noguchi S; Okada M; Inukai T
    Arzneimittelforschung; 1992 Jun; 42(6):787-94. PubMed ID: 1418032
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Results of a clinical trial of levoprotiline].
    Höschl C; Filip V; Bornová L; David I; Karen P; Seifertová D
    Cesk Psychiatr; 1992 Jun; 88(2):97-105. PubMed ID: 1505054
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predicting therapeutic results with levoprotiline and maprotiline in major depression: the role of the outcome criteria.
    Filip V; Höschl C; Karen P; Seifertová D; Bornová L; Prasková H; Prasko J
    Br J Psychiatry Suppl; 1993 Sep; (21):35-8. PubMed ID: 8217066
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmaco-EEG profile of maroxepine: third example to discuss the predictive value of pharmaco-electroencephalography in early human pharmacological evaluations of psychoactive drugs.
    Herrmann WM; Schärer E; Wendt G; Delini-Stula A
    Pharmacopsychiatry; 1991 Nov; 24(6):214-24. PubMed ID: 1812498
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Quantitative EEG characteristics of the state of depressive phase and the state of remission in major depression].
    Suzuki H; Mori T; Kimura M; Endo S
    Seishin Shinkeigaku Zasshi; 1996; 98(6):363-77. PubMed ID: 8810860
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [The baseline EEG traits and the induced EEG changes by chronic antidepressant medication in patients with major depression. Early prediction of clinical outcomes solely based on quantification and mapping of EEG].
    Ohashi Y
    Seishin Shinkeigaku Zasshi; 1994; 96(6):444-60. PubMed ID: 7938309
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Double-blind, placebo-controlled pharmacodynamic studies with a nutraceutical and a pharmaceutical dose of ademetionine (SAMe) in elderly subjects, utilizing EEG mapping and psychometry.
    Arnold O; Saletu B; Anderer P; Assandri A; di Padova C; Corrado M; Saletu-Zyhlarz GM
    Eur Neuropsychopharmacol; 2005 Oct; 15(5):533-43. PubMed ID: 16046102
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predictive value of pharmaco-electroencephalography in early human-pharmacological evaluations of psychoactive drugs. First example: savoxepine.
    Herrmann WM; Schärer E; Delini-Stula A
    Pharmacopsychiatry; 1991 Nov; 24(6):196-205. PubMed ID: 1687485
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Maprotiline versus fluvoxamine: comparison of their effects on the hypothalamo-hypophyseal-thyroid axis].
    De Mendonça Lima CA; Vandel S; Bonin B; Bechtel P; Carron R
    Encephale; 1997; 23(1):48-55. PubMed ID: 9172968
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Changes in the rat brain 5-HT1A and 5-HT2 receptors after chronic administration of levoprotiline, (+)-oxaprotiline and other antidepressant drugs.
    Klimek V; Zak-Knapik J; Cannizzaro C
    Pol J Pharmacol Pharm; 1992; 44(6):549-60. PubMed ID: 1305956
    [TBL] [Abstract][Full Text] [Related]  

  • 13. All-night EEG power spectral analysis of the cyclic alternating pattern components in young adult subjects.
    Ferri R; Bruni O; Miano S; Plazzi G; Terzano MG
    Clin Neurophysiol; 2005 Oct; 116(10):2429-40. PubMed ID: 16112901
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of effect of levoprotiline and dosulepine on cardial functions.
    Rysánek R; Mayer P; Náhunek K; Svestka J; Cesková E
    Act Nerv Super (Praha); 1989 Dec; 31(4):283. PubMed ID: 2638112
    [No Abstract]   [Full Text] [Related]  

  • 15. EEG power spectra at early stages of depressive disorders.
    Grin-Yatsenko VA; Baas I; Ponomarev VA; Kropotov JD
    J Clin Neurophysiol; 2009 Dec; 26(6):401-6. PubMed ID: 19952564
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmaco-EEG profiles of typical and atypical antidepressants.
    Saletu B
    Adv Biochem Psychopharmacol; 1982; 32():257-68. PubMed ID: 7090895
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The use of electrophysiological techniques to project typical psychotropic drug effects: some examples (author's transl)].
    Herrmann WM; Kubicki S
    EEG EMG Z Elektroenzephalogr Elektromyogr Verwandte Geb; 1981 Mar; 12(1):21-32. PubMed ID: 6112131
    [TBL] [Abstract][Full Text] [Related]  

  • 18. EEG default mode network in the human brain: spectral regional field powers.
    Chen AC; Feng W; Zhao H; Yin Y; Wang P
    Neuroimage; 2008 Jun; 41(2):561-74. PubMed ID: 18403217
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Video rating analysis of effect of maprotiline in patients with dementia and depression.
    Fuchs A; Hehnke U; Erhart C; Schell C; Pramshohler B; Danninger B; Schautzer F
    Pharmacopsychiatry; 1993 Mar; 26(2):37-41. PubMed ID: 8378411
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Possible contributory role of the central histaminergic system in the forced swimming model.
    Noguchi S; Fukuda Y; Inukai T
    Arzneimittelforschung; 1992 May; 42(5):611-3. PubMed ID: 1530672
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.